Responsibilities
Health economics
Economic evaluation
Pharmaceuticals
HTA
Clinical research
Epidemiology
Osteoporosis
Projects and publications
- Gunhild Hagen, Torbjørn Wisløff, (2021). Registry data for use in health technology assessments in Norway – Opportunities and challenges. Norsk Epidemiologi s. 19-27. doi: 10.5324/nje.v29i1-2.4042
- Gunhild Hagen, Jon Magnussen, Grethe Seppola Tell, Tone Kristin Omsland, (2019). Estimating the future burden of hip fractures in Norway. A NOREPOS study.. Bone s. 1-7. doi: 10.1016/j.bone.2019.115156
- Camilla Andreasen, Lene Bergendal Solberg, Trude Basso, Tove Tveitan Borgen, Cecilie Dahl, Torbjørn Wisløff, Gunhild Hagen, Ellen M Apalset, Jan-Erik Gjertsen, Wender Figved, Lars Michael Hübschle, Jens-Meinhard Stutzer, Jan Elvenes, Ragnar Martin Joakimsen, Unni Syversen, Erik Fink Eriksen, Lars Nordsletten, Frede Jon Frihagen, Tone Kristin Omsland, Åshild Bjørnerem, (2018). Effect of a Fracture Liaison Service on the Rate of Subsequent Fracture Among Patients With a Fragility Fracture in the Norwegian Capture the Fracture Initiative (NoFRACT): A Trial Protocol. JAMA Network Open doi: 10.1001/jamanetworkopen.2018.5701
- Gunhild Hagen, Torbjørn Wisløff, Ivar Sønbø Kristiansen, (2016). The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention—the impact of cardiovascular effects. Osteoporosis International s. 2089-2098. doi: 10.1007/s00198-016-3495-9
- Anders Prestmo, Gunhild Hagen, Olav Sletvold, Jorunn L. Helbostad, Pernille Thingstad, Kristin Taraldsen, Stian Lydersen, Vidar Halsteinli, Turi Saltnes, Sarah Lamb, Lars Gunnar Johnsen, Ingvild Saltvedt, (2015). Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial. The Lancet s. 1623-1633. doi: 10.1016/S0140-6736(14)62409-0
- Pernille Thingstad, Kristin Taraldsen, Gunhild Hagen, Sylvi Sand, Ingvild Saltvedt, Olav Sletvold, Jorunn L. Helbostad, (2015). Effectiveness of Task Specific Gait and Balance Exercise 4Months After Hip Fracture: Protocol of a Randomized Controlled Trial - The Eva-Hip Study. Physiotherapy Research International s. 87-99. doi: 10.1002/pri.1599
- Torbjørn Wisløff, Gunhild Hagen, Marianne Klemp, (2014). Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. PharmacoEconomics (Auckland) s. 601-612. doi: 10.1007/s40273-014-0152-z
- Torbjørn Wisløff, Gunhild Hagen, Vida Hamidi, Espen Movik, Marianne Klemp, Jan Abel Olsen, (2014). Estimating QALY gains in applied studies: A review of cost-utility analyses published in 2010. PharmacoEconomics (Auckland) s. 367-375. doi: 10.1007/s40273-014-0136-z
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2013). Helseøkonomisk evaluering ved Nasjonalt kunnskapssenter for helsetjenesten. Norsk Epidemiologi s. 157-164. doi: 10.5324/nje.v23i2.1638
- Vida Hamidi, Tove Ringerike, Gunhild Hagen, Åsmund Reikvam, Marianne Klemp, (2013). NEW ANTICOAGULANTS AS THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT. International Journal of Technology Assessment in Health Care s. 234-243. doi: 10.1017/S0266462313000251
- Gunhild Hagen, Geir Smedslund, Eva Marie-Louise Denison, Beate Charlotte Fagerlund Kvist, Gunn Eva Næss, (2021). Bronchial thermoplasty for the treatment of severe ashma: A single technology assessment
- Kateryna Porkhun, Gunhild Hagen, (2021). Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy
- Ingrid Kristine Ohm, Torunn Elisabeth Tjelle, Christopher James Rose, Vida Hamidi, Gunhild Hagen, Atle Fretheim, (2020). Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment
- Gunhild Hagen, Ulrikke Højslev Lund, Atle Fretheim, Vida Hamidi, (2019). Disease modifying treatments for relapsing remitting multiple sclerosis. A health economic evaluation.
- Gunhild Hagen, Anders Huitfeldt, Per Olav Vandvik, (2019). Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke
- Torbjørn Wisløff, Tove Ringerike, Gunhild Hagen, Åsmund Reikvam, Marianne Klemp, (2013). Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation
- Vigdis Lauvrak, Inger Natvig Norderhaug, Gunhild Hagen, Espen Movik, Ganesh Acharya, Anne Forus, Bjørn Hofmann, Synnøve Lian Johnsen, Anne Kaasen, Kari Klungsøyr Melve, Trond Markestad, Kjell Å Salvesen, Annetine Staff, Gisle Roksund, Marianne Klemp, Brynjar Fure, (2012). Tidlig ultralyd i svangerskapsomsorgen
- Tove Ringerike, Vida Hamidi, Gunhild Hagen, Åsmund Reikvam, Marianne Klemp, (2011). Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery
- Gunhild Hagen, Torbjørn Wisløff, Jan Falch, Cathrine Lofthus, Frede Frihagen, Knut-Arne Wensaas, Lars Granum, Janicke Nevjar, Ivar Sønbø Kristiansen, Marianne Klemp, (2011). Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway
- Espen Movik, Kristin Kamilla Linnestad, Gunhild Hagen, Hege Kornør, Ingrid Harboe, Marianne Klemp, (2011). Biologiske legemidler i behandling av tidlig leddgikt (revmatoid artritt)
- Ingvil von Mehren Sæterdal, Tove Ringerike, Jan Odgaard-Jensen, Ingrid Harboe, Gunhild Hagen, Åsmund Reikvam, Marianne Klemp, (2010). Legemidler til røykeslutt
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2010). Cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation
- Gunhild Hagen, Torbjørn Wisløff, Jan Falch, Cathrine Lofthus, Frede Frihagen, Knut-Arne Wensaas, Lars Granum, Janicke Nevjar, Ivar Sønbø Kristiansen, Marianne Klemp, (2010). Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway
- Kristian Samdal, Gunhild Hagen, Elmira Flem, Marianne Klemp Gjertsen, (2009). Kostnadseffektivitet av å inkludere vaksinasjon mot rotavirus i det norske barnevaksinasjonsprogrammet
- Eva Pike, Kristin Kamilla Linnestad, Gunhild Hagen, Aileen Rae Neilson, Torbjørn Wisløff, Marianne Klemp Gjertsen, (2008). Sammenligning av palonosetron og ondansetron med hensyn på klinisk nytte og kostnad/effekt ved forebygging av kvalme og oppkast i forbindelse med kjemoterapi hos kreftpasienter
- Gunhild Hagen, (2022). Produksjonsvirkninger i metodevurdering – hvordan blir kostnadseffektiviteten?. Dagens medisin
- Gunhild Hagen, Hannisdahl Elisabeth, Christopher James Rose, Therese Kristine Dalsbø, (2020). Hvor effektive er legemidler til behandling av plakkpsoriasis?. Sykepleien Forskning doi: 10.4220/Sykepleienf.2020.81878
- Gunhild Hagen, Torbjørn Wisløff, Ivar Sønbø Kristiansen, (2016). Bør Tine rekruttere melkedrikkere?. Aftenposten (morgenutg. : trykt utg.)
- Lars Gunnar Johnsen, Anders Prestmo, Olav Sletvold, Jorunn L. Helbostad, Gunhild Hagen, Vidar Halsteinli, Pernille Thingstad, Kristin Taraldsen, Turid Saltnes, Ingvild Saltvedt, (2015). Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial. .
- Olav Sletvold, Anders Prestmo, Gunhild Hagen, Jorunn L. Helbostad, Stian Lydersen, Vidar Halsteinli, Kristin Taraldsen, Pernille Thingstad, Sarah Lamb, Ingvild Saltvedt, (2015). The Trondheim Hip Fracture Trial-A breakthrough for acute orthogeriatric care..
- Gunhild Hagen, (2015). Helseøkonomisk evaluering som del av klinisk forskning. Tidsskrift for Den norske legeforening doi: 10.4045/tidsskr.15.0025
- Ingvild Saltvedt, Anders Prestmo, Gunhild Hagen, Jorunn L. Helbostad, Pernille Thingstad, Kristin Taraldsen, Vidar Halsteinli, Stian Lydersen, Turi Saltnes, Sarah Lamb, Olav Sletvold, Lars Gunnar Johnsen, (2014). Use of health care services and cost-effectiveness of comprehensive geriatric care in hip-fracture patients - The Trondheim Hip Fracture Trial.
- Gunhild Hagen, (2014). Cost-effectiveness of Calcium and Vitamin D supplementation for fracture prevention accounting for cardiovascular side effects.
- Gunhild Hagen, (2014). Cost-effectivness of comprehensive geriatric care as compared to orthopeadic care for elderly hip fractue patients.
- Gunhild Hagen, Torbjørn Wisløff, Espen Movik, Vida Hamidi, Marianne Klemp, (2014). Reporting of QALY estimation in applied and published cost-effectiveness analyses.
- Gunhild Hagen, Anders Prestmo, Olav Sletvold, Ingvild Saltvedt, Stian Lydersen, Lars Gunnar Johnsen, Jorunn L. Helbostad, Turi Saltnes, Kristin Taraldsen, Pernille Thingstad, Sarah Lamb, Vidar Halsteinli, (2014). Cost effectiveness of treating elderly hip fracture patients with comprehensive geriatric care as compared to orthopaedic care.
- Gunhild Hagen, Kim Rand-Hendriksen, Gudrun Maria Waaler Bjørnelv, Maria Knoph Kvamme, Ivar Sønbø Kristiansen, (2013). Bør prioriteringer QALYfiseres?. Dagens medisin
- Torbjørn Wisløff, Gunhild Hagen, Marianne Klemp, (2013). Comparative effectiveness research on the new anticoagulants - Do we need it?. Value in Health s. A297-A297.
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2013). Towards a paradigm shift in anticoagulation? Too soon to conclude on cost-effectiveness of new anticoagulants. Value in Health s. A289-A290.
- Gunhild Hagen, Vida Hamidi, Espen Movik, Jan Abel Olsen, Torbjørn Wisløff, (2012). Measuring QALY gains in practice: A Review of 315 CEA/CUA published in 2010.
- Gunhild Hagen, (2012). Osteoporose og kostnader.
- Gunhild Hagen, (2012). Introduksjon til helseøkonomisk modellering og hvordan helseøkonomisk modellering brukes i Norge i dag.
- Gunhild Hagen, (2012). Hva koster osteoporose helse-Norge.
- Gunhild Hagen, (2011). Kostnadseffektivitet av legemidler til røykeslutt.
- Gunhild Hagen, (2011). Kan anbefalingene i veilederen være vanskelige å forstå og følge når analyser skal gjennomføres?.
- Gunhild Hagen, (2011). Introduksjon i bruk av modellering i helseøkonomiske analyser: hvorfor modellere, og grunnleggende verktøy til å komme i gang med modellering.
- Gunhild Hagen, Kristian Samdal, Marianne Klemp, (2011). HTA of including rotavirus vaccination in the Norwegian childhood immunisation programme.
- Torbjørn Wisløff, Gunhild Hagen, Kim Rand-Hendriksen, (2011). Half-cycle correction and Simpson’s method tested in different health economic models – does it matter which method we use?.
- Vida Hamidi, Gunhild Hagen, Tove Ringerike, Marianne Klemp, (2011). Health economic evaluation of thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin in patients undergoing elective hip- or knee replacement surgery.
- Vida Hamidi, Gunhild Hagen, Tove Ringerike, Marianne Klemp, (2011). Health economic evaluation of thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin in patients undergoing elective hip- or knee replacement surgery.
- Gunhild Hagen, Torbjørn Wisløff, Marianne Klemp, (2010). Cost-effectiveness of Drugs for Smoking Cessation in Norway.
- Gunhild Hagen, Torbjørn Wisløff, Ivar Sønbø Kristiansen, Marianne Klemp, (2009). Cost-effectiveness of first-line treatment for osteoporosis when the drug goes generic.
- Kristian Samdal, Gunhild Hagen, Elmira Flem, Marianne Klemp, (2009). Cost-effectiveness of childhood vaccination against rotavirus in Norway.